Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299265 | 0.87 | AKR1B1 (0.37) | AKR1B1ALOX12BACE1KCNH2AR | |
| SCHEMBL12299015 | 0.86 | AKR1B1 (0.32) | AKR1B1BACE1 | |
| SCHEMBL12300142 | 0.74 | AKR1B1 (0.36) | AKR1B1ALOX12AR | |
| SCHEMBL12299271 | 0.73 | AKR1B1 (0.33) | AKR1B1BACE1 | |
| SCHEMBL14053664 | 0.66 | AKR1B1 (0.43) | AKR1B1BACE1KCNH2AR | |
| SCHEMBL14053922 | 0.66 | AKR1B1 (0.43) | AKR1B1BACE1KCNH2AR | |
| SCHEMBL27278870 | 0.66 | AKR1B1 (0.75) | AKR1B1 | |
| SCHEMBL2375239 | 0.65 | BACE1 (0.42) | AKR1B1BACE1 | |
| SCHEMBL1822169 | 0.65 | AKR1B1 (0.44) | AKR1B1ALOX12BACE1KCNH2AR | |
| SCHEMBL12299286 | 0.64 | AR (0.35) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | AKR1B1 2656/4885ALOX12 2925/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.